Wire
Bernstein Raises CVS Health Price Target to $112 From $106
CVS Health (CVS) has an average rating of overweight and mean price target of $114.58, according to analysts polled by FactSet.Price: $94.08, Change: $-1.22, Percent Change: -1.28%
$CVS
$CVS
35 stories mentioning CVSUpdated 2d ago
Every FINWIRES story that references CVS, newest first.
What are analysts saying about CVS?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on CVS?
Wire
Bernstein Adjusts CVS Health Price Target to $106 From $112, Maintains Outperform Rating
CVS Health (CVS) has an average rating of overweight and mean price target of $114.58, according to analysts polled by FactSet.Price: $95.19, Change: $-0.88, Percent Change: -0.92%
$CVS
Wire
CVS Health Reports Availability of Updated COVID-19 Vaccines
CVS Health (CVS) said Thursday updated 2026-2027 COVID-19 vaccines are now available at its CVS Pharmacy and MinuteClinic locations.The company said the vaccines are for patients at no-cost with most insurance plans.Price: $97.25, Change: $+0.02, Percent Change: +0.02%
$CVS
Wire
Market Chatter: HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology
The US Department of Health and Human Services is planning to create two deputy commissioner roles at the Food and Drug Administration to focus on technology and drugs, respectively, CNBC reported Tuesday, citing sources.Specifically, the technology deputy commissioner role would focus on the intersection of health and artificial intelligence, the report said, citing the sources.HHS officials would appoint the new deputies in what some within the Trump administration view as an attempt to wield greater influence over the agency, the sources reportedly told CNBC.HHS didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $398.06, Change: $-0.70, Percent Change: -0.18%
$CNC$CVS$ELV$HUM$UNH
Wire
HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports
HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports
$CNC$CVS$ELV$HUM$UNH
Sectors
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In corporate news, Eli Lilly (LLY) shares rose 4.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 3.8%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares added 0.6%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose 3.5%, and Bristol Myers Squibb fell 3.2%.Charles River Laboratories (CRL) on Wednesday reported fiscal Q2 non-GAAP earnings and sales above market expectations and raised its 2026 non-GAAP EPS guidance. Its shares jumped 11%.
$AZN$BMY$CRL$CVS$LLY$NVO
US Markets
CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views
CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-consumer weight-management offerings, while both companies reported higher-than-expected second-quarter results Wednesday.The collaboration with drugmaker Lilly will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy via the CVS Health app, the retail pharmacy chain said. The tie-up promises to offer transparent pricing, including reimbursed and self-pay options, for the drugs by early in the fourth quarter.Lilly didn't immediately respond to' request for comment on the collaboration.The collaboration is part of a broader effort by CVS to enhance its DTC weight-management program, with MinuteClinic digital weight-loss visits lowered to $29, among other things. CVS Pharmacy offers all Food and Drug Administration-approved Glucagon-like peptide-1s, whether through insurance or cash-pay options.Separately, CVS reported that its second-quarter adjusted earnings rose to $2.58 a share from $1.81 a year earlier, exceeding the FactSet-polled consensus of $1.85. Revenue grew 7.3% to $106.1 billion, topping Wall Street's $100.03 billion views.The company now expects 2026 adjusted EPS between $7.90 and $8.10, compared with its prior outlook range of $7.30 to $7.50 and above the Street's $7.45 forecast. The updated guidance accounts for gains in the healthcare benefits and pharmacy and consumer wellness segments "while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds" CVS said in an earnings release.Separately, Lilly reported non-GAAP EPS of $8.38 for the June quarter, up from $6.31 a year earlier, surpassing the FactSet-polled consensus of $6.17. Revenue surged 48% to $22.97 billion, while analysts projected $20.69 billion.The drugmaker raised its 2026 revenue outlook to a range of $85 billion to $87 billion from the previous guidance of $82 billion to $85 billion. The company narrowed its full-year non-GAAP EPS forecast to between $35.50 and $36.50 from its previous range of $35.50 to $37. Analysts are looking for full-year non-GAAP EPS of $35.16 on revenue of $85.39 billion."(The second quarter) continued Lilly's strong momentum," Chief Executive David Ricks said on an earnings call, according to a FactSet transcript. "We delivered robust revenue across all key products and major geographies."Lilly shares were up 4.1% in Wednesday afternoon trade, while CVS fell 5.1%.Price: $99.45, Change: $-4.98, Percent Change: -4.76%
$CVS$LLY
Sectors
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie in a patent-infringement case involving its compounded semaglutide nasal spray. Novo shares rose 1.3%.AstraZeneca (AZN) and Bristol Myers Squibb (BMY) are not engaged in discussions over a potential merger, Reuters reported Wednesday, citing a senior source close to the matter. AstraZeneca shares rose nearly 4%, and Bristol Myers Squibb fell 3.5%.
$AZN$BMY$CVS$LLY$NVO
Sectors
Sector Update: Healthcare
Healthcare stocks advanced Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1%.The iShares Biotechnology ETF (IBB) increased 0.9%.In corporate news, Eli Lilly (LLY) shares rose 3.7% after it posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance. Separately, CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. CVS shares were down 4.9%.
$CVS$LLY
Wire
Top Midday Stories: SpaceX Shares Fall After Inaugural Results; AMD Drops Despite Strong Q2 EPS, Revenue
US equities were mixed and crude oil eased in late-morning trading Wednesday as investors remained hopeful that a deal to reopen the Strait of Hormuz may be reached soon by the US and Iran.In company news, Space Exploration Technologies (SPCX) reported a Q2 loss late Tuesday of $0.09 per diluted share, narrowing from the loss of $0.34 a year earlier. Analysts surveyed by FactSet expected a loss of $0.23. Revenue rose to $7.81 billion from $4.07 billion, topping the $6.83 billion consensus. CEO Elon Musk said SpaceX will build its AI services exclusively on Nvidia's (NVDA) systems. SpaceX shares fell 8.6% around midday, and Nvidia rose 3.4%.Advanced Micro Devices (AMD) reported fiscal Q2 adjusted diluted EPS late Tuesday of $1.66, up from $0.48 a year earlier, above the $1.62 consensus. Revenue rose to $11.64 billion from $7.69 billion, exceeding the $11.31 billion market estimate. The company expects Q3 revenue of $13 billion, plus or minus $300 million, compared with the $12.54 billion consensus. AMD shares fell 6.8%.Shopify (SHOP) reported Q2 EPS of $1.16, up from $0.69 a year earlier and above the $0.30 consensus. Revenue rose to $3.58 billion from $2.68 billion, exceeding the $3.43 billion estimate. The company expects Q3 revenue to gain more than 30%. Shopify shares jumped 17%.Walt Disney (DIS) reported fiscal Q3 adjusted diluted EPS of $2.06, up from $1.61 a year earlier and above the $1.86 consensus. Revenue rose to $25.25 billion from $23.65 billion, trailing the $25.39 billion estimate. Disney shares rose 1.9%.Eli Lilly (LLY) reported Q2 non-GAAP EPS of $8.38, up from $6.31 a year earlier and above the $6.01 consensus. Revenue rose to $22.97 billion from $15.56 billion, topping the $20.69 billion consensus. The company expects full-year non-GAAP EPS of $35.50 to $36.50, compared to previous guidance of $35.50 to $37. Revenue is expected to be $85 billion to $87 billion, up from the prior forecast of $82 billion to $85 billion. Analysts expect EPS of $35.04 on revenue of $85.28 billion. Separately, CVS Health (CVS) is revamping its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Lilly. Shares of Lilly rose 2.8%, and CVS dropped 5.8%.Uber Technologies (UBER) reported Q2 non-GAAP EPS of $0.81, up from $0.60 a year earlier and matching the consensus. Revenue rose to $14.19 billion from $12.65 billion, trailing the $14.24 billion consensus. The company expects Q3 non-GAAP EPS of $0.84 to $0.88, compared with the $0.87 market estimate. Uber shares fell 6.6%.Price: $114.57, Change: $-10.77, Percent Change: -8.59%
$AMD$CVS$DIS$LLY$NVDA$SHOP$SPCX$UBER
Sectors
Sector Update: Healthcare Stocks Rise Premarket Wednesday
Healthcare stocks were rising premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.9% and the iShares Biotechnology ETF (IBB) up 0.4%.Eli Lilly (LLY) shares were up more than 4% after the company posted higher Q2 non-GAAP earnings and revenue in addition to raising its 2026 sales guidance.CVS Health (CVS) reported higher Q2 adjusted earnings and revenue, and lifted its 2026 non-GAAP EPS outlook. Shares of CVS Health were down more than 7% pre-bell.Cencora (COR) stock was up more than 2% after the company posted higher fiscal Q3 adjusted earnings and revenue in addition to lifting its fiscal 2026 non-GAAP EPS outlook.
$COR$CVS$IBB$LLY$XLV
US Markets
Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings
The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing optimism over a potential deal to reopen the Strait of Hormuz, while investors await the latest batch of corporate earnings.The S&P 500 and the Dow Jones Industrial Average rose 0.3% each before the opening bell, while the Nasdaq edged up 0.1%. The S&P 500 and the Dow recorded fresh all-time highs on Tuesday, while the Nasdaq advanced for a fourth consecutive session.President Donald Trump reportedly said late Tuesday that an agreement to reopen the Strait of Hormuz, the world's most important chokepoint for crude flows, is imminent, following "very good discussions" with Iran, according to CNBC.Treasury Secretary Scott Bessent told CNBC on Tuesday that a potential deal to open the crucial waterway could be reached this week. Qatar's Foreign Ministry spokesperson Majed al-Ansari reportedly said that efforts to resolve the US-Iran conflict are "in very progressive stages."West Texas Intermediate crude oil increased 1.1% to $76.58 a barrel in premarket action, while Brent gained 1.7% to $80.73.Yemen's Iran-aligned Houthis reportedly claimed an attack on a Saudi Arabian tanker near the coast of Yanbu, a major port for Saudi crude oil exports, according to a separate CNBC report.Treasury yields were mixed before the open, with the two-year rate rising 1.2 basis points to 4.21% while the 10-year rate retreated 1 basis point to 4.62%.Eli Lilly (LLY), Walt Disney (DIS), Shopify (SHOP), Uber Technologies (UBER), CVS Health (CVS), Phillips 66 (PSX), Kraft Heinz (KHC) and Global Payments (GPN) are scheduled to report their latest financial results before the bell, among others.Sandisk (SNDK), AppLovin (APP), McKesson (MCK), DoorDash (DASH), eBay (EBAY) and Expedia (EXPE) post their earnings after the markets close.Shares of SpaceX (SPCX) dropped 12% pre-bell after the rocket and satellite company reported quarterly results for the first time since going public. Advanced Micro Devices (AMD) fell 8.6% even though it recorded fiscal second-quarter results above market estimates. Arista Networks (ANET) jumped 16%.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the ADP Employment report for July at 8:15 am. The purchasing managers' index composite final report from S&P Global (SPGI) for July is out at 9:45 am, followed by the Institute for Supply Management's services index for the same month at 10 am.The domestic EIA petroleum inventories report is due at 10:30 am.Federal Reserve Governor Lisa Cook is scheduled to speak at 4:05 pm, while San Francisco Fed President Mary Daly speaks at 8:35 pm.Gold gained 1.5% to $4,215 per troy ounce, while bitcoin slipped 0.2% to $64,146.
Dow JonesNasdaq CompositeS&P 500$AMD$ANET$APP$CVS$DASH$DIS$EBAY$EXPE$GPN$KHC$LLY$MCK$PSX$SHOP$SNDK$SPCX$SPGI$UBER
Wire
CVS Health Teams With Eli Lilly to Expand GLP-1 Access
CVS Health (CVS) said Wednesday it revamped its direct-to-consumer weight management program, lowering the cost of virtual visits and expanding access to GLP-1 medications through a collaboration with Eli Lilly (LLY).CVS Health said eligible patients will be able to access transparent pricing, including reimbursed and self-pay options, for Eli Lilly's Zepbound and Foundayo through its app by early in the fourth quarter, with as-early-as same-day pickup at one of about 9,000 pharmacies.CVS Pharmacy offers all US Food and Drug Administration-approved GLP-1 medications.CVS also lowered the cost of MinuteClinic virtual weight-loss visits to $29, offering eligible patients access to licensed clinicians with no membership or recurring fee, it added.Shares of CVS Health and Eli Lilly were up 3.8% and 4.6%, respectively, in premarket trading.
$CVS$LLY
Wire
Deutsche Bank Adjusts CVS Health Price Target to $116 From $92
CVS Health (CVS) has an average rating of overweight and mean price target of $112.71, according to analysts polled by FactSet.Price: $107.19, Change: $-2.15, Percent Change: -1.97%
$CVS
Wire
CVS Health Opens Pharmacy-Focused Location in Houston
CVS Health (CVS) said Friday it opened its first pharmacy-focused site in Houston, Texas, featuring a full-service pharmacy along with a selection of over-the-counter products.The company said two more pharmacy-focused locations are planned in the greater Houston area over the next year.CVS Health said it intends to open around 20 pharmacy-focused sites in select communities across the US and over 40 new CVS Pharmacy locations, including traditional stores and pharmacies in Target.Price: $107.16, Change: $+0.66, Percent Change: +0.62%
$CVS
Wire
CVS Caremark Reaches Settlement With FTC to Deliver Affordable Prescription Medicine
CVS Caremark (CVS) said Tuesday it has reached a global settlement with the Federal Trade Commission, which further advances the company's ability to deliver affordable prescription drugs.The settlement resolves all outstanding FTC litigation and investigations related to CVS Health, involving rebate, pharmacy network contracting, and vertical integration issues, the company said.Many of the measures in the agreement align with CVS Caremark's current affordability and transparency efforts, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model, each meant to reduce patient costs and offer greater clarity about drugs, the company added.Price: $105.94, Change: $+0.04, Percent Change: +0.04%
$CVS
Wire
Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
(Updates with Claritev's response in the fourth paragraph.)The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said."We decline to comment on any matters before the DOJ, according to longstanding policy," a DOJ spokesperson told. "However, we can affirm that under the Trump Administration this DOJ will continue to prioritize affordability for all Americans across our economy.""Claritev previously disclosed both the closure of the DOJ's criminal antitrust investigation and the company's receipt of a civil investigative demand ("CID")," a Claritev spokesperson said in an emailed statement to. "The CID does not make findings or allegations, and Claritev is fully cooperating with the DOJ in providing the information it seeks."(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $28.59, Change: $-1.26, Percent Change: -4.21%
$CI$CTEV$CVS$UNH
Wire
Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
(Update with the Justice Department's response to a request for comment in the third paragraph.)The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said."We decline to comment on any matters before the DOJ, according to longstanding policy," a DOJ spokesperson told. "However, we can affirm that under the Trump Administration this DOJ will continue to prioritize affordability for all Americans across our economy."Claritev didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $26.49, Change: $-3.35, Percent Change: -11.23%
$CI$CTEV$CVS$UNH
Wire
Market Chatter: DOJ Expands Antitrust Probe Into Claritev
The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said.Claritev and the Justice Department didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $27.91, Change: $-1.93, Percent Change: -6.47%
$CI$CTEV$CVS$UNH
Wire
CVS Health Keeps Quarterly Dividend at $0.665 a Share, Payable Aug. 3 to Holders of Record on July 23
CVS Health Keeps Quarterly Dividend at $0.665 a Share, Payable Aug. 3 to Holders of Record on July 23
$CVS
Showing 1-20 of 35
